James Moy to Immunoglobulin G
This is a "connection" page, showing publications James Moy has written about Immunoglobulin G.
Connection Strength
1.464
-
Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga?) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study. J Clin Immunol. 2017 Aug; 37(6):603-612.
Score: 0.590
-
Longitudinal Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Antibody Responses and Identification of Vaccine Breakthrough Infections Among Healthcare Workers Using Nucleocapsid Immunoglobulin G. J Infect Dis. 2022 Nov 28; 226(11):1934-1942.
Score: 0.213
-
Neutralizing Antibody Activity to Severe Acute Respiratory Syndrome Coronavirus 2 Delta (B.1.617.2) and Omicron (B.1.1.529) After 1 or 2 Doses of BNT162b2 Vaccine in Infection-Naive and Previously Infected Individuals. J Infect Dis. 2022 10 17; 226(8):1407-1411.
Score: 0.212
-
Intravenous immunoglobulin 10% in children with primary immunodeficiency diseases. Immunotherapy. 2018 10; 10(14):1193-1202.
Score: 0.158
-
Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: Analysis of a phase III, multicentre, prospective, open-label study. Eur J Pharm Sci. 2018 Jun 15; 118:80-86.
Score: 0.154
-
Modified ARCHITECT? serologic assays enable plasma-level performance from dried blood spot samples. Biotechniques. 2022 10; 73(4):193-203.
Score: 0.053
-
Expanding access to SARS-CoV-2 IgG and IgM serologic testing using fingerstick whole blood, plasma, and rapid lateral flow assays. J Clin Virol. 2021 08; 141:104855.
Score: 0.048
-
Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex? 10% Versus Gammaplex? 5% in Subjects with Primary Immunodeficiency. J Clin Immunol. 2017 Apr; 37(3):301-310.
Score: 0.036